Status:
COMPLETED
Intravenous Versus Oral Administration of Prednisolone in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Isala
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
Treatment with systemic corticosteroids for acute exacerbations of COPD results in the improvement of clinical outcomes. The optimal route of administration has not been rigorously studied in COPD. Up...
Eligibility Criteria
Inclusion
- Exacerbation of COPD (at least Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] severity stage II)
- Smoking history of \> 10 pack years
Exclusion
- Signs of severe exacerbation (arterial pH \< 7.26 or pCO2 \> 9.3 kPa)
- History of asthma
- Significant or unstable co-morbidity
- Participated in another study 4 weeks before admission
- Previously randomized to this study
- Findings on chest radiography other than those fitting with signs of COPD
- Known hypersensitivity to prednisolone
- Non-compliant
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
End Date :
August 1 2003
Estimated Enrollment :
256 Patients enrolled
Trial Details
Trial ID
NCT00311961
Start Date
June 1 2001
End Date
August 1 2003
Last Update
August 26 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Isala Klinieken
Zwolle, Overijssel, Netherlands, 8000 GM